Sanofi India Limited (SANOFI) Share Price

NSE · Healthcare · Drug Manufacturers - General · ISIN INE058A01010

₹3,206.00+15.20 (+0.48%)

Key metrics

Market Cap
₹7,345 Cr
P/E Ratio
22.46
EPS
140.5
Book Value
325.31
P/B Ratio
9.8
ROE
43.61%
ROCE
59.19%
Debt / Equity
0.02
Net Margin
17.92%
Revenue Growth
-8.33%
Profit Growth
-20.99%
Dividend Yield
7.6%
52W High
₹5,175.50
52W Low
₹3,054.00
Market Cap Band
mid cap
Face Value
10

Ratios computed from the annual results period ending 2025-12-31.

About Sanofi India Limited

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited operates as a subsidiary of Hoechst GmbH.

Headquarters
Mumbai, India
Employees
1,097
Promoter Holding
60.6%

The full Sanofi India Limited analysis

Create a free account to open the complete SANOFI deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.

  • 10-year financialsIncome statement, balance sheet and cash flow, year by year.
  • Valuation & fair valueFair-value estimates, quality scores and a value grade.
  • Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
  • Shareholding historyPromoter, FII, DII and public holdings across every quarter.
  • Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
  • Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.